Table 1.
Synchronous malignant lymphoma and lung cancer in the literature
| Year/ref. | Age /gender | Lung cancer | Malignant lymphoma | Treatment | Outcome | Survival time (months) |
|---|---|---|---|---|---|---|
| 1999/[8] | 71/F | SCC | TCL/lung | lobectomy + chemotherapy(CHOP) | died of progression of lymphoma | 7 |
| 2000/[9] | 67/M | SCC | MALToma/lung | lobectomy + chemotherapy (THP-COP) | died of pulmonary fibrosis due to chemotherapy | 11 |
| 2001/[10] | 74/M | Adenoca | MALToma/lung | lobectomy | alive | 12 |
| 2002/[11] | 67/M | SCC | MALToma/lung | lobectomy + chemotherapy (CHOP + carboplastin plus taxol) | alive | 6 |
| 2008/[12] | 73/M | Adenoca | MCL/pleura | chemotherapy Endoxan + Farmorubicin + Vincristine) | alive | 14 |
| 2008/[13] | 74/M | Adenoca | MALToma/lung | lobectomy, NHL was left untreated | N/A | N/A |
| 2012/[14] | 60/F | Adenoca | MALToma/lung | lobectomy, NHL was left untreated | N/A | N/A |
| 2017/[15] | 45/M | Adenoca | MCL/lung | 6 cures of alternating RCHOP and RDHAP (dexamethasone, high-dose Ara-Cytarabine and cisplatin) + autologous stem cell transplantation. | died of treatment complications | 36 |
| 2020/[16] | 69/F | Adenoca | MALToma/lung |
lobectomy + chemotherapy (CHOP) |
alive | 12 |
| 2020/[17] | 64/M | SCC | MALToma/lung | N/A | N/A | N/A |
| 2021/(The current case) | 75/M | Adenoca | DLBCL/stomach | RFA + chemotherapy(R-CHOP) + Radioactive seed implantation | alive | 27 |
| 2023/[18] | 63/M | SCC | MALToma/lung | surgical resection | alive | N/A |
SCC: squamous cell carcinoma; Adenoca: Adenocarcinoma; TCL: T-cell lymphoma; MALToma: Mucosa-associated lymphoid tissue lymphoma; MCL: Mantle cell lymphoma; DLBCL: diffuse large B-cell lymphoma; THP-COP: cyclophosphamide, pirarubicin, vincristine, and prednisolone